Next 10 |
2024-05-01 10:23:01 ET More on SELLAS Life Sciences, TG Therapeutics, etc. Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout TG Therapeutics: The Cloud Over Briumvi TG Therapeutics: BRIUMVI Development Could Lead To Great Results TG The...
- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall Response Rate in Patients with ASXL1 Mutation in the SLS009 30mg BIW Cohort to Date, Al...
2024-04-29 08:54:27 ET More on SELLAS Life Sciences Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout SELLAS Life Sciences GAAP EPS of -$1.34 misses by $0.24 SELLAS Life Sciences looks to raise $20M in a direct offering Seeking Alpha...
– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients Treatment and Follow-Up Without Any Modifications – – IDMC Will Convene Again Ahead of Scheduled IDMC Charter M...
2024-04-19 13:49:43 ET Summary SELLAS Life Sciences Group, Inc. is a late-stage biotech company with a leading drug candidate, Galinpepimut-S, or GPS, that has a 44% probability of success and a potential 9x return. GPS is an immunotherapy drug targeting the Wilms Tumor 1 antigen,...
2024-03-28 16:57:07 ET More on SELLAS Life Sciences SELLAS Life Sciences looks to raise $20M in a direct offering Sellas Life Sciences gains on securing orphan drug status for r/r PTCL treatment Seeking Alpha’s Quant Rating on SELLAS Life Sciences Hist...
2024-03-28 16:54:11 ET More on SELLAS Life Sciences SELLAS Life Sciences looks to raise $20M in a direct offering Sellas Life Sciences gains on securing orphan drug status for r/r PTCL treatment Seeking Alpha’s Quant Rating on SELLAS Life Sciences Re...
Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified Biomarkers - Completed Enrollment in Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April - - Phase 2a study of SLS009 in r/r AML: 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20%; 100...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall Response Rate in Patients with ASXL1 Mutation in the SLS009 30mg BIW Cohort to Date, Al...
– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Tria...
– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients Treatment and Follow-Up Without Any Modifications – – IDMC Will Convene Again Ahead of Scheduled IDMC Charter M...